Zymeworks, Inc.

Zymeworks, Inc.

Zymeworks, Inc.

Overview
Date Founded

2017

Headquarters

1385 West 8th Avenue, Suite 540, Vancouver, BC, V6H 3V9, CAN

Type of Company

Public

Employees (Worldwide)

355

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Contact Data
Trying to get in touch with decision makers at Zymeworks, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder, President & Chief Executive Officer

Executive Vice President, Business Operations & Chief Financial Officer

Chief Commercial Officer

Executive Vice President, Early Development & Chief Scientific Officer

Chief Medical Officer

Chief People Officer

Head of Discovery Research

Senior Vice President, Technical & Manufacturing Operations

Senior Vice President, Regulatory

Vice President, Pharmacovigilance

Board of Directors

Team Member at Sodexho, Inc.

Former President & Chief Executive Officer at Foundation Medicine, Inc.

Former President & Chief Executive Officer at Onyx Pharmaceuticals, Inc.

Former President at Eli Lilly & Company

Head-Therapeutics at 23andMe, Inc.

Founder, President & Chief Executive Officer at Zymeworks, Inc.

Former Managing Director at Baker Bros. Advisors LP

Chief Medical Officer at Harpoon Therapeutics, Inc.

Paths to Zymeworks, Inc.
Potential Connections via
Relationship Science
You
Zymeworks, Inc.
Owners & Shareholders
Details Hidden

Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately $7.3 billion across our strategies.

Details Hidden

Eventide uses values-based analyses and fundamental, technical and risk analyses in selecting and recommending securities for investment. The firm also engages with sub-advisers concerning values-based criteria in connection with fixed-income securities held by certain Funds. Their investment process begins with a top-down analysis to select a variety of asset classes and/or sectors believed to offer opportunities for current income and/or capital appreciation. Eventide manages portfolios actively and this may involve frequent trading that negatively affects investment performance and increases transaction costs and taxes.

Details Hidden

Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund firm which focuses primarily on the health care and consumer sectors. They invest predominantly in equities and can be opportunistic across the capital structure. The firm seeks to maximize the opportunity set of investment candidates allowing for the selection of unique, concentrated bets to generate uncorrelated returns. They maintain significant position and portfolio level hedges in an effort to mitigate basis and market risks. Armistice Capital employs a bottom-up analysis, assessing all components of the company’s capital structure and aims to take larger positions where the greatest potential risk adjusted return exists. Armistice Capital’s Domestic Fund and the Offshore Fund, through their investments in the Master Fund, seek to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing in distressed debt, value equities and event equities. In all of its investing activities, the Funds will seek to emphasize capital preservation and will seek to mitigate risk through various hedging strategies at both the position and portfolio levels.

Recent Transactions
Details Hidden

Zymeworks, Inc. issued . USD Common Shares

Details Hidden

Zymeworks, Inc. issued USD Common Shares

Details Hidden

Zymeworks, Inc. issued USD Common Shares

Transaction Advisors
Escrow Agent

Advised onZymeworks, Inc. issued . USD Common Shares

Legal Advisor

Advised onZymeworks, Inc. issued . USD Common Shares

Underwriter

Advised onZymeworks, Inc. issued . USD Common Shares

Legal Advisor

Advised onZymeworks, Inc. issued . USD Common Shares

Legal Advisor

Advised onZymeworks, Inc. issued . USD Common Shares

Underwriter

Advised onZymeworks, Inc. issued . USD Common Shares

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner at Fenwick & West LLP

Advisor

Chief Medical Officer at Lengo Therapeutics

Clients

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $82.6 billion during calendar year 2020. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson's pharmaceutical arm is Janssen Pharmaceutica.

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Key Stats and Financials As of 2020
Market Capitalization
$1.3B
Total Enterprise Value
$1.96B
Earnings Per Share
$-3.58
Revenue
$39M
EBITDAMargin
-454.9%
Total Debt
$8.66M
EBITDA
$-177M
Total Equity
$410M
Net Profit
$-181M
Enterprise Value / Sales
50.41x
TEVNet Income
-10.87x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
-8.04%
Investors
Details Hidden

Investor at NGINX Software, Inc.

Details Hidden

FMR help over 32 million people feel more confident in their most important financial goals, manage employee benefit programs for over 22,000 businesses, and support more than 13,000 financial institutions with innovative investment and technology solutions to grow their businesses.

Details Hidden

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo.The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Suppliers
Daiichi Sankyo Co Ltd. Wholesale: Consumer Non-Durables/Sundries | Tokyo, Japan

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

CDRD Ventures, Inc. Pharmaceuticals | Vancouver, Canada

CDRD Ventures, Inc. engages in the development and production of therapeutic products. The company is headquartered in Vancouver, Canada.

Competitors
AstraZeneca Plc Pharmaceuticals - Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

MacroGenics, Inc. Pharmaceuticals - Rockville, MD

MacroGenics is a leader in the discovery and development of innovative medicinces that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe. Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms: Our Dual-Affinity Re-Targeting (DART™) platform enables us to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; Our Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and Our Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Zymeworks, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Zymeworks, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Zymeworks, Inc..